Aclaris is currently advancing ATI-2138 in a Phase 2a clinical trial for atopic dermatitis and aims to explore its broader therapeutic potential in multiple inflammatory diseases. Data generated ...
Hosted on MSN9d
Aclaris Therapeutics Unveils Promising Data on ATI-2138, a Novel Dual ITK/JAK3 InhibitorAclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced significant findings about ATI-2138, a novel investigational drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback